Email Us Here

Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform

The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials.